Robert Bessler Sells 75,000 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 75,000 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $8.55, for a total transaction of $641,250.00. Following the transaction, the director directly owned 1,236,948 shares in the company, valued at approximately $10,575,905.40. This represents a 5.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Robert Bessler also recently made the following trade(s):

• On Friday, April 24th, Robert Bessler sold 62,147 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.05, for a total transaction of $438,136.35.
• On Thursday, April 23rd, Robert Bessler sold 7,752 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total transaction of $54,264.00.
• On Tuesday, April 21st, Robert Bessler sold 5,101 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.01, for a total transaction of $35,758.01.

LifeStance Health Group Price Performance

LFST stock opened at $7.93 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.48 and a quick ratio of 1.65. The company’s 50-day moving average is $6.84 and its 200-day moving average is $6.74. The stock has a market capitalization of $3.08 billion, a PE ratio of 132.17 and a beta of 1.20. LifeStance Health Group, Inc. has a 1 year low of $3.74 and a 1 year high of $8.89.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Wednesday, May 6th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. LifeStance Health Group had a return on equity of 1.56% and a net margin of 1.55%.The business had revenue of $403.48 million during the quarter, compared to analyst estimates of $387.46 million. LifeStance Health Group’s revenue was up 21.2% compared to the same quarter last year. Equities research analysts expect that LifeStance Health Group, Inc. will post 0.08 EPS for the current fiscal year.

LifeStance Health Group announced that its Board of Directors has approved a share buyback plan on Wednesday, February 25th that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the company to buy up to 3.6% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

LFST has been the topic of a number of research reports. UBS Group upped their target price on LifeStance Health Group from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Zacks Research upgraded shares of LifeStance Health Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 27th. BTIG Research upped their price objective on shares of LifeStance Health Group from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Barclays raised their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company an “overweight” rating in a research note on Friday, March 6th. Finally, Canaccord Genuity Group lifted their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, LifeStance Health Group has an average rating of “Buy” and an average target price of $10.00.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Royal Bank of Canada raised its position in LifeStance Health Group by 63.4% in the 1st quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock valued at $468,000 after buying an additional 27,244 shares during the last quarter. AQR Capital Management LLC boosted its holdings in LifeStance Health Group by 223.0% during the 1st quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after acquiring an additional 35,554 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of LifeStance Health Group by 3.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock worth $952,000 after acquiring an additional 4,169 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of LifeStance Health Group by 1.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock worth $4,100,000 after acquiring an additional 11,331 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of LifeStance Health Group by 10.2% in the second quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company’s stock valued at $2,847,000 after purchasing an additional 51,154 shares during the last quarter. Institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.